In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Is Your Organization Digitally Mature?

Executive Summary

We're in our final weeks. This is your last chance to take the assessment developed specifically for In Vivo readers, based on the McKinsey Digital QuotientTM assessment to begin thinking through how digitally savvy your organization is (free survey.)

Digital innovation is high on the C-suite agenda, but what does it mean? How do you get started? Where do you invest?

Biopharma, medtech and diagnostics companies that want to keep up — or move ahead — must build innovative business models, test and invest in new capabilities and transform their cultures. When organizations do all of that effectively, they’re rewarded with better financial performance.

McKinsey & Co.'s Digital QuotientTM is a metric for measuring the digital maturity of companies. McKinsey has assessed digital readiness in multiple industries and now they are partnering with In Vivo to do a deep dive in biopharma, medtech and diagnostics.

Click here to take the Digital Quotient assessment and begin thinking through how digitally savvy your organization is.  





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts